Gut Microbiota and Related Electronic Multisensorial System Changes in Subjects With Symptomatic Uncomplicated Diverticular Disease Undergoing Rifaximin Therapy

Frontiers in Medicine

article

Antonio De Vincentis¹  Giorgio Pennazza²  Lorenza Putignani³  Michele Pier Luca Guarino⁵  Michele Cicala⁵  Raffaele Antonelli Incalzi¹  Marco Santonico⁶  Federica Del Chierico³  Annamaria Altomare⁵  Benedetta Marigliano⁷  Alice Laudisio⁸  Sofia Reddel³  Simone Grasso⁶  Alessandro Zompanti² 

[1] Unit of Internal Medicine, University Campus Bio Medico of Rome;Unit of Electronics for Sensor Systems, Department of Engineering, University Campus Bio-Medico di Roma;Multimodal Laboratory Medicine Research Area, Unit of Human Microbiome, Bambino Gesù Children's Hospital, Istituto di Ricovero e Cura a Carattere Scientifico;Department of Diagnostic and Laboratory Medicine, Unit of Microbiology and Diagnostic Immunology, Unit of Parasitology and Multimodal Laboratory Medicine Research Area, Unit of Human Microbiome, Bambino Gesù Children's Hospital, Istituto di Ricovero e Cura a Carattere Scientifico;Unit of Gastroenterology, University Campus Bio Medico of Rome;Unit of Electronics for Sensor Systems, Department of Science and Technology for Humans and the Environment, University Campus Bio-Medico di Roma;Emergency Department, Azienda Ospedaliera San Camillo Fornanini;Unit of Geriatrics, University Campus Bio Medico of Rome

关键词: microbiota;    e-tongue;    e-nose;    diverticular disease;    rifaximin;   

DOI  :  10.3389/fmed.2021.655474

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

Background: Intestinal dysbiosis might play a pathogenetic role in subjects with symptomatic uncomplicated diverticular disease (SUDD), but the effect of rifaximin therapy has been scantly explored with regard to gut microbiota variations in patients with SUDD. Aims: To verify to which extent rifaximin treatment affects the gut microbiota and whether an electronic multisensorial assessment of stools and breath has the potential for detecting these changes. Methods: Breath and stool samples were collected from consecutive patients with SUDD before and after a 7 days' therapy with rifaximin. Stool microbiota was assessed, and the electronic multisensorial assessment was carried out by means of the BIONOTE electronic (e-)tongue in stools and (e-)nose in breath. Results: Forty-three subjects (female 60%, median age 66 years) were included, and 20 (47%) reported clinical improvement after rifaximin therapy. Alpha and beta diversity of stool microbiota did not significantly change after treatment, while a significant variation of selected taxa was shown (i.e., Citrobacter, Coprococcus, Anaerotruncus, Blautia, Eggerthella lenta, Dehalobacterium, SMB53 , and Haemophilus parainfluenzae ). Overall, the electronic multisensorial system suboptimally mirrored microbiota changes, but it was able to efficiently predict patients' clinical improvement after rifaximin with accuracies ranging from 0.81 to 0.98. Conclusions: In patients with SUDD, rifaximin administration is associated with significant variation of selected taxa. While inaccurate in predicting gut microbiota change, an electronic multisensorial system, made up of e-tongue and e-nose, was able to predict clinical improvement, thus potentially qualifying as an easy and cheap tool to forecast subjects taking most likely benefit from rifaximin therapy.

【 授权许可】

CC BY